Publications
Koshkin VS, Sonpavde GP. Expanding the Reach of FGFR Inhibitors to Advance Precision Medicine in Urothelial Carcinoma. European urology. 2024. PMID: 39578126
Lozano-Esparza S, Sánchez-Blas HR, Huitzil-Meléndez FD, Meneses-Medina MI, Van Loon K, Potter MB, Mohar A, Lajous M. Colorectal cancer survival in Mexico: Leveraging a national health insurance database. Cancer epidemiology. 2024. PMID: 39577055
Rosenthal KJ, Gordan JD, Scott JD. Protein kinase A and local signaling in cancer. The Biochemical journal. 2024. PMID: 39540434
Li M, Hannan LM, Goyal L, Bocobo AG, Parks AL, Bauer K, Baiev I, Dinicola C, Gordan JD, Venook AP, Harris WP, Bracci P, Kelley RK. Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma-a real-world, multicenter study. Therapeutic advances in medical oncology. 2024. PMID: 39563717
Li M, Hannan LM, Goyal L, Bocobo AG, Parks AL, Bauer K, Baiev I, Dinicola C, Gordan JD, Venook AP, Harris WP, Bracci P, Kelley RK. Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma-a real-world, multicenter study. Therapeutic advances in medical oncology. 2024. PMID: 39563717
Li M, Hannan LM, Goyal L, Bocobo AG, Parks AL, Bauer K, Baiev I, Dinicola C, Gordan JD, Venook AP, Harris WP, Bracci P, Kelley RK. Changes in alpha-fetoprotein across the systemic therapy continuum in advanced hepatocellular carcinoma-a real-world, multicenter study. Therapeutic advances in medical oncology. 2024. PMID: 39563717
Jabbour EJ, Kantarjian HM, Goekbuget N, Shah BD, Chiaretti S, Park JH, Rijneveld AW, Gore L, Fleming S, Logan AC, Ribera JM, Menne TF, Mezzi K, Zaman F, Velasco K, Boissel N. Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab. Blood cancer journal. 2024. PMID: 39562780
Jabbour EJ, Kantarjian HM, Goekbuget N, Shah BD, Chiaretti S, Park JH, Rijneveld AW, Gore L, Fleming S, Logan AC, Ribera JM, Menne TF, Mezzi K, Zaman F, Velasco K, Boissel N. Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab. Blood cancer journal. 2024. PMID: 39562780
Yang Y, Badura ML, O'Leary PC, Delavan HM, Robinson TM, Egusa EA, Zhong X, Swinderman JT, Li H, Zhang M, Kim M, Ashworth A, Feng FY, Chou J, Yang L. Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer. Nature cancer. 2024. PMID: 39558146
Yang Y, Badura ML, O'Leary PC, Delavan HM, Robinson TM, Egusa EA, Zhong X, Swinderman JT, Li H, Zhang M, Kim M, Ashworth A, Feng FY, Chou J, Yang L. Transcription and DNA replication collisions lead to large tandem duplications and expose targetable therapeutic vulnerabilities in cancer. Nature cancer. 2024. PMID: 39558146
Singh N, Früh M, Gubens MA, Ismaila N, Daly ME. Management of Stage III Non-Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update Clinical Insights. JCO oncology practice. 2024. PMID: 39556773
Joseph NM, Umetsu SE, Kim GE, Terry M, Perry A, Bergsland E, Kakar S. Progression of Low-Grade Neuroendocrine Tumors (NET) to High-Grade Neoplasms Harboring the NEC-Like Co-alteration of RB1 and TP53. Endocrine pathology. 2024. PMID: 39556303
Ribrag V, Iglesias L, De Braud F, Ma B, Yokota T, Zander T, Spreafico A, Subbiah V, Illert AL, Tan D, Santoro A, Munster PN, Suehiro Y, Wang Y, Ji DM, Chen S, Beltz K, Suenaga N, Ramkumar T, Luo F, Lai C, Wainberg ZA. A first-in-human phase 1/2 dose-escalation study of MAK683 (EED inhibitor) in patients with advanced malignancies. European journal of cancer (Oxford, England : 1990). 2024. PMID: 39793445
Morrow WP, Milligan NS, Ohgami RS, Young KH, Wang B, Vega F, Marques-Piubelli ML, Feldman AL, Slack GW, Savage KJ, Zhao X, Rubenstein JL, Hsi ED. Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors. Journal of hematopathology. 2024. PMID: 39549220
Chen LY, Thibaud S, Bodnar S, Chari A, Richter J, Cho HJ, Sanchez LJ, Rodriguez C, Rossi AC, Richard S, Parekh S, Jagannath S. MRD-negative duration following latest line of therapy predicts long-term PFS in real-world multiple myeloma patients. Blood advances. 2024. PMID: 39546749
Geng H, Mo SS, Chen L, Ballapuram A, Tsang M, Lu M, Rauschecker AM, Wen KW, Devine WP, Solomon DA, Rubenstein JL. Identification of Genomic Biomarkers of Disease Progression and Survival in Primary CNS Lymphoma. Blood advances. 2024. PMID: 39536287
Luck C, Jacobs KA, Okimoto RA. The Capicua C1 Domain is Required for Full Activity of the CIC::DUX4 Fusion Oncoprotein. Cancer Research Communications. 2024. PMID: 39530749
Mennillo E, Lotstein ML, Lee G, Johri V, Ekstrand C, Tsui J, Hou J, Leet DE, He JY, Mahadevan U, Eckalbar W, Oh DY, Fragiadakis GK, Kattah MG, Combes AJ. Single-cell spatial transcriptomics of fixed, paraffin-embedded biopsies reveals colitis-associated cell networks. bioRxiv : the preprint server for biology. 2024. PMID: 39605355
Bazhenova L, Kim DW, Cho BC, Goel S, Heist R, Werner TL, Eaton KD, Wang JS, Pant S, Adkins DR, Blakely CM, Yan X, Neuteboom S, Christensen JG, Chao R, Bauer T. Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study. Future oncology (London, England). 2024. PMID: 39513224
Kim J, Munster PN. Estrogens and breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology. 2024. PMID: 39522613